Cell line · CVCL_1923
Papers36
1 to 20 of 36
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Intravenously deliverable oncolytic virus VET3-TGI favorably alters the tumor microenvironment. | J Immunother Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Collagen-Binding IL-15 Immunocytokine Armed Oncolytic Adenovirus Establishes a Self-Reinforcing Immunostimulatory Milieu to Potentiate Antitumor Immunity. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Enfortumab vedotin induces immunogenic cell death and shows enhanced preclinical antitumor activity when combined with a PD-1 inhibitor. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Microfluidic Nano-Assembly of Red-Blood-Cell (RBC) Lipids and Components for Engineering Extracellular Vesicles. | Adv Healthc Mater | 2026 | Its Methods give the RRID and name the line | PubMed | |
| mTORC1 suppression by Trp53 mutation drives resistance to immune checkpoint blockade. | Cell Death Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting KDM3B Elicits Anti-tumor Immunity by Alleviating SHP1-mediated STING Suppression in Triple-Negative Breast Cancer. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting the Vim-PGI2 Pathway Enhances CD8+ T Cell-Mediated Antitumor Immunity in Breast Cancer. | Hum Mutat | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PD-1 Blockade-Induced DKK1 Expression by CD8+ T Cells Promotes Blood-Brain Barrier Permeabilization. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Micro-Organ Chip Deciphers Tumor-Derived G-CSF as Remote Commander of Lung Pre-Metastatic Niche via VEGFA-KDR Cascade. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| FAM135B Deficiency Inhibits Cytotoxic T-cell Activity in Triple-Negative Breast Cancer by Blocking the IFI16-Dependent STING Pathway. | Cancer Immunol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeted Delivery of a Potent STING Agonist Payload via an Antibody-Drug Conjugate Drives Robust Antitumor Activity in Preclinical Models. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Non-orthosteric inhibition of enolase 1 impedes growth of triple-negative breast cancer. | Cell Rep Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Overexpression of RUNX2 promotes breast cancer multi-organ metastasis through stabilizing c-Myc. | Cell Death Dis | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Modulation of fibronectin extracellular matrix enhances anti-tumor efficacy of immune checkpoint blockade. | Cell Rep Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Ammonia Suppresses the Antitumor Activity of Natural Killer Cells and T Cells by Decreasing Mature Perforin. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Potentiating anti-tumor immunity by re-engaging immune synapse molecules. | Cell Rep Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer. | Cancer Immunol Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNFα Inflammation. | Cancer Immunol Res | 2025 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1923/papers